In a report released today, Kumaraguru Raja from CIM Securities initiated coverage with a Buy rating on Arcturus Therapeutics Ltd (NASDAQ: ARCT) and a price target of $23. The company’s shares closed yesterday at $8.71.
According to TipRanks.com, Raja is a 1-star analyst with an average return of -2.1% and a 60.9% success rate. Raja covers the Healthcare sector, focusing on stocks such as Corbus Pharmaceuticals, Acer Therapeutics Inc, and Tonix Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcturus Therapeutics Ltd with a $20.50 average price target, implying a 135.4% upside from current levels. In a report issued on September 20, WBB Securities also upgraded the stock to Buy.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.19 and a one-year low of $4.78. Currently, Arcturus Therapeutics Ltd has an average volume of 22.01K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcturus Therapeutics Ltd. operates as preclinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of RNA medicines using proprietary lipid-mediated delivery system (LUNAR) and UNA Oligomer chemistry technologies. The company was founded in March 2013 and is headquartered in San Diego, CA.
